Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: L01XC03

Herwenda(trastuzumab)

Breast Neoplasms;Stomach Neoplasms

Marketing Authorisation Holder: Sandoz GmbH

EMA Authorisation: 15/11/2023

INN: trastuzumab

Indication

Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Herwenda — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.